Open international conference • Keynotes • Oral presentations • Posters | Dates: 19–21 May 2027 | Venue: Vienna, Austria
participation@executivecongresses.com Submit Abstract
EECCTM 2027 logo
EECCTM 2027
Programme • Vienna
Keynotes • Oral presentations • Posters • Clinical translation • Scientific exchange

Official Programme 12th European Congress on Clinical & Translational Medicine

The EECCTM 2027 programme is designed as a multidisciplinary forum for clinical and translational medicine, bringing together keynote perspectives, original research presentations, poster discussions, and focused scientific exchange. Across the programme, participants can engage with developments in clinical research, precision medicine, biomarkers, therapeutics, digital health, implementation science, and evidence-to-practice translation while building meaningful professional connections.

Day 1 Day 2 Day 3 Posters
Congress overview

An international scientific programme combining keynote expertise, clinical research, translational science, oral presentations, poster interaction, and professional networking.

Scientific programme
Dates
19–21 May 2027
Location
Vienna, Austria
See venue details
Presenter pathway
Abstract → Acceptance → Registration
Non-presenting delegates may register directly.
Submit Abstract → Register
Business Address: 98 Theobalds Rd, London WC1X 8WB, UK
Keynote programme
Leading perspectives

Featured leaders address emerging priorities, translational challenges, and developments shaping contemporary clinical medicine.

Scientific presentations
Research in discussion

Oral sessions create space for focused presentation, critical discussion, and exchange across diverse areas of clinical and translational research.

Poster programme
Interactive research exchange

Poster discussions support direct interaction with authors, detailed exploration of research findings, and informal scientific dialogue.

Conference focus
From evidence to practice

The programme connects discovery, clinical evidence, patient outcomes, implementation, and collaborative pathways toward real-world impact.

Day 1 • Wednesday, 19 May 2027

Opening Ceremony, Keynote Programme, Oral Presentations & Networking

The opening day establishes the scientific direction of EECCTM 2027 through featured keynote sessions, parallel oral presentations, and dedicated opportunities for professional networking.

Keynotes • Oral sessions
08:30–09:00
Registration & Welcome Coffee

Delegate check-in, programme orientation, informal introductions, and preparation for the opening scientific sessions.

09:00–09:15
Opening Ceremony & Welcome Address

Formal opening of EECCTM 2027 and introduction to the three-day clinical and translational medicine programme.

09:15–09:40
Keynote 01 Featured Leader
Translational Strategy & Clinical Research Infrastructure
Professor James Allan
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, United Kingdom
25-minute keynote slot including presentation and discussion/Q&A.
09:40–10:05
Keynote 02 Featured Leader
Pathophysiology, Biomarkers & Translational Mechanisms
Dr. Clerici Mario Salvatore
Department of Pathophysiology and Transplantation, University of Milan, Italy
25-minute keynote slot including presentation and discussion/Q&A.
10:05–10:30
Keynote 03 Featured Leader
Neuroscience Translation & Precision Neurology
Prof Rejko Krüger
Full Professor in Neurosciences – FNR PEARL Chair, University of Luxembourg
25-minute keynote slot including presentation and discussion/Q&A.
10:30–10:55
Keynote 04 Featured Leader
Bioethics, Trust & Responsible Innovation
Prof. Effy Vayena
Professor of Bioethics at the Swiss Institute of Technology (ETH), Switzerland
25-minute keynote slot including presentation and discussion/Q&A.
11:15–11:40
Keynote 05 Featured Leader
Advanced Therapeutics & Translational Innovation
Professor Adrian Gardner
Aston University, United Kingdom
25-minute keynote slot including presentation and discussion/Q&A.
11:40–12:05
Keynote 06 Featured Leader
Outcomes, Clinical Evidence & Implementation
Dr. Margot A. Cousin
Mayo Clinic, USA
25-minute keynote slot including presentation and discussion/Q&A.
12:05–12:30
Keynote 07 Featured Leader
Translational Pathology & Biomarker Discovery
Dr. Demetrios Braddock
Professor of Pathology, Yale School of Medicine, USA
25-minute keynote slot including presentation and discussion/Q&A.
12:30–12:55
Keynote 08 Featured Leader
Clinical Practice Translation & Care Delivery
Dr. Ying Wang
Professor of Medicine, Indiana University School of Medicine, USA
25-minute keynote slot including presentation and discussion/Q&A.
10:55–11:15
Coffee & Networking Break

Refreshments and discussion among keynote leaders, presenters, delegates, researchers, clinicians, and participating organisations.

13:00–14:00
Networking Lunch

Open seating for scientific discussion, interdisciplinary introductions, and collaboration across clinical, academic, and industry participants.

14:00–15:20 • Parallel Scientific Sessions

Parallel Oral Presentations

Confirmed scientific presentations are scheduled across parallel rooms, with dedicated presentation and discussion time for each contributor.

Parallel oral sessions
Parallel Room A

Scientific Presentations — Room A

14:00–14:20 Oral 01
The Anticancer Drug Mitoxantrone Triggers the Formation of Ribosome-enriched Stress Granules Independently of the Classical Translational Control Pathways
Witold Szaflarski
Department of Histology and Embryology, Poznan University of Medical Sciences, Poland
14:20–14:40 Oral 02
Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial
Jeffrey A. How
Division of Surgery, The University of Texas MD Anderson Cancer Center, USA
14:40–15:00 Oral 03
Steroid-sparing biologics in severe asthma and chronic obstructive pulmonary disease: a systematic review, cross-disease meta-analysis, and translational estimate of corticosteroid-related harm prevented
Lorenzo Carriera
Faculty of Medicine and Surgery, Università Cattolica del Sacro Cuore, Italy
15:00–15:20 Oral 04
Translational framework combining machine learning and in vivo screening for aminoglycoside ototoxicity prevention
Eunjung Han
Zebrafish Translational Medical Research Center, Korea University, Republic of Korea
Parallel Room B

Scientific Presentations — Room B

14:00–14:20 Oral 05
Preclinical and early clinical safety of intra-articular spheroid adipose-derived stem cells for knee osteoarthritis: A translational study
Satoshi Sobajima
Sobajima Clinic and Medical Institute for Regenerative Medicine, Japan
14:20–14:40 Oral 06
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Maciej Cieśla
Mol Polish Academy of Sciences, Poland
14:40–15:00 Oral 07
Translational Insights Into Myocardial Deformation and Fibrosis in Hypertrophic Cardiomyopathy Using Diffusion Tensor MRI
Oumaima Laghzali
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Germany
15:00–15:20 Oral 08
Development and Validation of a Streamlined Workflow for Proteomic Analysis of Proteins and Post-translational Modifications from Dried Blood
Matthew W. Foster
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, USA
15:20–15:40
Afternoon Tea & Networking

Refreshment break following the parallel oral sessions.

15:40–16:20
Clinical & Translational Discussion Forum

Cross-disciplinary discussion connecting the day's keynote themes and oral presentations with practical challenges in clinical translation, evidence generation, and implementation.

16:20–17:00
Welcome Networking Reception

Informal networking reception for keynote leaders, presenters, poster authors, delegates, partners, and collaborators.

Day 2 • Thursday, 20 May 2027

Keynote Programme, Oral Sessions, Dedicated Poster Programme & Scientific Exchange

Day 2 combines featured keynote sessions with parallel oral presentations, a dedicated poster programme, and extended opportunities for scientific discussion and interdisciplinary exchange.

Keynotes • Oral sessions • Posters
08:30–09:00
Morning Coffee & Networking

Arrival coffee and informal discussion before the second-day keynote programme.

09:00–09:25
Keynote 09 Featured Leader
Precision Medicine & Integrative Translation
Dr. Fu-Jen Tsai
School of Chinese Medicine, China Medical University, China
25-minute keynote slot including presentation and discussion/Q&A.
09:25–09:50
Keynote 10 Featured Leader
Digital Transformation & Clinical Innovation
Professor Devi Mohan
The University of Queensland, Australia
25-minute keynote slot including presentation and discussion/Q&A.
09:50–10:15
Keynote 11 Featured Leader
Clinical Therapeutics & Outcome-led Medicine
Professor Francis Ka-Leung Chan
The Chinese University of Hong Kong
25-minute keynote slot including presentation and discussion/Q&A.
10:15–10:40
Keynote 12 Featured Leader
Future Clinical Research & Translational Training
Yao-An Shen
College of Medicine, Taipei Medical University, Taiwan
25-minute keynote slot including presentation and discussion/Q&A.
11:00–11:25
Keynote 13 Featured Leader
Precision Cardiovascular Medicine & Genomic Translation
Prof Roger Foo Sik Yin
National University of Singapore, Singapore
25-minute keynote slot including presentation and discussion/Q&A.
11:25–11:50
Keynote 14 Featured Leader
Translational Science Operations & Research Facilitation
Professor Sumimasa Nagai
Department for Advancing Translational Science, Kyoto University, Japan
25-minute keynote slot including presentation and discussion/Q&A.
11:50–12:15
Keynote 15 Featured Leader
Data Integration, Systems Biology & Precision Translation
Professor IMOTO Seiya
Institute of Medical Science, The University of Tokyo, Japan
25-minute keynote slot including presentation and discussion/Q&A.
12:15–12:40
Keynote 16 Featured Leader
Cellular Translation & Clinically Relevant Oncology
Lee Jin Ku
Seoul National University College of Medicine, Seoul, South Korea
25-minute keynote slot including presentation and discussion/Q&A.
10:40–11:00
Coffee & Networking Break

Refreshments and scientific exchange between the two Day 2 keynote blocks.

12:40–14:00
Networking Lunch

Lunch with open seating for presenter interaction, research discussion, and interdisciplinary networking.

14:00–15:20 • Parallel Scientific Sessions

Parallel Oral Presentations

Confirmed scientific presentations are scheduled across parallel rooms, with dedicated presentation and discussion time for each contributor.

Parallel oral sessions
Parallel Room A

Scientific Presentations — Room A

14:00–14:20 Oral 09
Biophotonics for pathogen detection and therapy: optical biosensing, phototherapy, and translational perspectives
Qinqin Ma
College of Life Science, Sichuan Normal University, China
14:20–14:40 Oral 10
Distribution of urinary neutrophil gelatinase-associated lipocalin and post-translationally modified fetuin-A in outpatients with acute kidney disease detected using a nationwide automatic detection system
Ya-Chi Lin
Department of Biomedical Informatics, China Medical University, Taiwan
14:40–15:00 Oral 11
Cerebrospinal Fluid Circulating Tumor DNA Profiling in Central Nervous System Metastases from Solid Tumors: A Prospective Multicentre Translational Analysis of the BrainStorm (OncoDistinct-006) Study
Luca Arecco
Hôpital Universitaire de Bruxelles (H.U.B) Clinical Trials Center, Belgium
15:00–15:20 Oral 12
Evaluating the Whole Blood Survival Advantage: How Citrate and Calcium Levels Drive Mortality in a Translational Swine Model of Polytrauma
Jason M. Rall
Wilford Hall Ambulatory Surgical Center, USA
Parallel Room B

Scientific Presentations — Room B

14:00–14:20 Oral 13
Vitamin D’s Capacity to Increase Amphetamine-Induced Dopamine Release in Healthy Humans: A Clinical Translational [11C]-PHNO Positron Emission Tomography Study
Patrick D. Worhunsky
West Virginia University School of Medicine Morgantown, United States
14:20–14:40 Oral 14
Stemness and clinical performance of water-jet technology: A translational study in breast reconstruction
Francesco De Francesco
Azienda Ospedaliera Universitaria Ospedali Riuniti, Italy
14:40–15:00 Oral 15
ISB clinical biomechanics award winner 2025: Residual translational and rotational kinematics after combined anterior cruciate ligament and anterolateral ligament reconstruction during walking – A biplanar fluoroscopy analysis
Joonho Wang
SKKU School of Medicine, South Korea
15:00–15:20 Oral 16
Translational reprogramming of TGF-β signaling via TRMT61A-mediated tRNA m1A drives prostatic fibrosis and hyperplasia
Hongbing Mei
Shenzhen Second People's Hospital, Clinical Medicine College of Anhui Medical University, China
15:20–15:40
Afternoon Tea Break

Refreshments before the dedicated poster session.

15:40–17:20 • Dedicated Poster Session

Poster Presentations & Author Interaction

Twenty-two poster presentations are grouped into a focused author-interaction session supporting direct discussion, emerging-research exchange, and networking across the conference themes.

Poster session
Poster 01 Day 2
Clinical magnetic resonance imaging-defined plaque morphology predicts guidewire crossing failure in below-the-knee occlusions in a translational model using amputated lower limbs
Alexander B. Crichton
University of Birmingham, UK
Poster 02 Day 2
Lipids and abdominal aortic aneurysm: from pathophysiology to therapy. A call to action from the Italian Society for the Study of Atherosclerosis and the Italian Society for Angiology and Vascular Medicine
Rossella Marcucci
Center for Atherothrombotic Disease, University of Florence, Italy
Poster 03 Day 2
Deep brain stimulation for management of treatment-refractory schizophrenia: A translational review for clinical integration
Cristina D. Ghinda
Department of Neurosurgery, Johns Hopkins University School of Medicine, USA
Poster 04 Day 2
Clinical needs and translational prospects of cardiovascular nanomedicine: Focus on intravascular and molecular imaging of atherosclerosis
Michael Joner
Deutsches Zentrum für Herz-Kreislauf-Forschung e. V., Germany
Poster 05 Day 2
The effect of culturally tailored continuity of midwifery care on perinatal outcomes for women having a first Nations baby in Victoria, Australia: a prospective non-randomised translational study
Della A. Forster
La Trobe University, Australia
Poster 06 Day 2
Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancer
E. Martinelli
Department of Precision Medicine, Università della Campania “Luigi Vanvitelli”, Naples, Italy
Poster 07 Day 2
Anti-pruritic and anti-inflammatory effects of Sopoongsan on atopic or seborrheic dermatitis: A pilot randomized, placebo-controlled clinical trial and translational research using in vitro and in vivo models
Hye-sun Lim
Korea Institute of Oriental Medicine, South Korea
Poster 08 Day 2
Prospective study of anamorelin in pancreatic cancer cachexia: Clinical and translational insights into response heterogeneity
Ryosuke Matsukane
Department of Pharmacy, Kyushu University Hospital, Japan
Poster 09 Day 2
Multi-day heart rate variability monitoring via Holter electrocardiogram for depression detection: Clinical validation and translational challenges
Shota Furukawa
Department of Neuropsychiatry, Keio University School of Medicine, Japan
Poster 10 Day 2
Translational peak frequency mapping of human sinoatrial node–Bachmann bundle axis: Integrating human in vivo electroanatomic mapping with preclinical microstructural validation
Luigi Pannone
Universitair Ziekenhuis Brussel, Belgium
Poster 11 Day 2
Upskilling in Healthy Longevity Medicine and Its Association With Physicians’ Implementation Intent and Self-Reported Clinical Confidence: Cross-Sectional Observational Study
Evelyne Bischof
Shanghai University of Medicine and Health Sciences, China
Poster 12 Day 2
Translational Analysis of NSD3 Gene Amplification in Lung Squamous Cell Carcinoma: Clinical and Prognostic Insights From Histopathologic Analysis of Patient Samples
Tetsuro Taki
Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Japan
Poster 13 Day 2
Systematic post-translational modification genome wide identifies therapeutic targets for Alzheimer’s disease: evidence from multi-cohort analysis
Xiaoming Wang
Huazhong University of Science and Technology, China
Poster 14 Day 2
Frontotemporal transcranial direct current stimulation for disorganized speech in schizophrenia: a translational hypothesis
Sergio Castaño Castaño
Department of Psychobiology, Faculty of Health Sciences, University of Burgos, Spain
Poster 15 Day 2
LncRNA HCP5 remodels G6PD dual post-translational modification to mediate metabolic adaptations driving osimertinib resistance in lung adenocarcinoma
Desong Yang
Central South University, Changsha, China
Poster 16 Day 2
The Translational Dermatology Initiative: Aiming at a New Disease Classification of Inflammatory Skin Diseases
Kilian Eyerich
Universitätsklinikum Freiburg, Freiburg im Breisgau, Germany
Poster 17 Day 2
Cellular immunology data enable clinical severity prediction via supervised machine learning
Dokyoon Kim
University of Pennsylvania, USA
Poster 18 Day 2
OPMD_TCM_PTM: a post-translational modification sites identification model for oral potentially malignant diseases’ traditional Chinese medicine proteins
Baitong Chen
The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, China
Poster 19 Day 2
Translational Pharmacokinetic/Pharmacodynamic Modeling to Inform Target Concentration and Dose Projection of A Novel Selective Estrogen Receptor Degrader (SIM0270) for Early Clinical Development
Jia Chen
Simcere Zaiming Pharmaceutical Co., Ltd., China
Poster 20 Day 2
Post-translational modifications in triple-negative breast cancer: research status and translation challenges
Yu Ding
Department of Breast and Thyroid, Guiyang Maternal and Child Health Care Hospital, China
Poster 21 Day 2
Neoadjuvant chemotherapy and bevacizumab for colorectal peritoneal metastases: clinical and translational outcomes of the phase II BEV-IP trial
Daryl Kai Ann Chia
Department of Surgery, National University Hospital, Singapore
Poster 22 Day 2
Targeting the retina-brain axis for early intervention: an observational and translational framework associating occupational stressors with probable dementia via HSP-mediated proteostasis
Lei Zhu
Anhui University of Science & Technology, China
17:20–17:45
Poster Networking & Day 2 Close

Final poster conversations, informal scientific exchange, and transition to the close of Day 2.

Day 3 • Friday, 21 May 2027

Final Four Keynotes, Scientific Presentations, Closing & Networking

The final day concludes the keynote programme with featured leaders, followed by further oral presentations, interdisciplinary discussion, and the formal conference close.

Keynotes • Oral sessions
08:30–09:00
Morning Coffee & Networking

Arrival coffee, informal networking, and preparation for the closing-day keynote programme.

09:00–09:25
Keynote 17 Featured Leader
Oncology Translation, Biomarkers & Precision Therapeutics
Byoung Chul Cho
Department of Medicine, Yonsei University College of Medicine, South Korea
25-minute keynote slot including presentation and discussion/Q&A.
09:25–09:50
Keynote 18 Featured Leader
Translational Oncology & Molecular Disease Mechanisms
Prof. Dr. Jonathan Sleeman
Medical Faculty Mannheim, Heidelberg University, Germany
25-minute keynote slot including presentation and discussion/Q&A.
09:50–10:15
Keynote 19 Featured Leader
Genetics, Molecular Biology & Translational Discovery
Dr. Juliette Godin
Institut de génétique et de biologie moléculaire et cellulaire, France
25-minute keynote slot including presentation and discussion/Q&A.
10:15–10:40
Keynote 20 Featured Leader
Biomarker Strategy & Personalized Medicine
Prof. A.J. van Gool
Faculty of Medical Sciences, Radboud University, The Netherlands
25-minute keynote slot including presentation and discussion/Q&A.
10:40–11:00
Coffee & Networking Break

Refreshments before the final parallel oral sessions.

11:00–12:20 • Final Parallel Scientific Sessions

Parallel Oral Presentations

Confirmed scientific presentations are scheduled across parallel rooms, with dedicated presentation and discussion time for each contributor.

Scientific presentations
Parallel Room A

Scientific Presentations — Room A

11:00–11:20 Oral 17
Liquid biopsy miRNA risk score in bladder cancer: Translational insights from patient-derived xenografts to prognostic stratification
Margaritis Avgeris
National and Kapodistrian University of Athens, Greece
11:20–11:40 Oral 18
Synthesis and Translational Assessment of Trinucleotide 5′-Cap Analogs for Messenger Ribonucleic Acid-Based Therapeutics
Jaeheon Lee
Research and Development Center, Hanmi Fine Chemical, Republic of Korea
11:40–12:00 Oral 19
EULAR recommendations for a core dataset to support clinical care and translational and observational research in systemic lupus erythematosus
Johanna Mucke
Department of Rheumatology, Heinrich-Heine University, Germany
12:00–12:20 Oral 20
Post-translational chemical modification of E3 ligase for efficient target protein degradation
Jongmin Park
Department of Chemistry, Kangwon National University, Republic of Korea
Parallel Room B

Scientific Presentations — Room B

11:00–11:20 Oral 21
Vitamin D and frailty: Clinical evidence, mechanistic insights, and translational challenges
Nicola Napoli
Department of Medicine and Surgery, Research Unit of Endocrinology and Diabetes, Università Campus Bio-Medico di Roma, Rome, Italy
11:20–11:40 Oral 22
CFTR rescue in W1282X cystic fibrosis patient-derived intestinal organoids (PDIOs) mediated by translational readthrough-inducing drugs (TRIDs)
Ivana Pibiri
Università degli Studi di Palermo, Italy
11:40–12:00 Oral 23
Sex Hormone Profiles in Patients With Torsades de Pointes Ventricular Tachycardia: A Clinical-Electrophysiological Translational Study
Pietro Enea Lazzerini
Università degli Studi di Siena, Siena, Italy
12:20–12:40
Closing Remarks & Conference Acknowledgements

Closing reflections, acknowledgements to keynote leaders, presenters, poster authors, delegates, partners, and the scientific community.

12:40–13:40
Networking Lunch

Final conference lunch with open seating for scientific, clinical, academic, and industry networking.

13:40–15:00
Open Networking, One-to-One Meetings & Collaboration Time

The formal scientific programme is complete. The afternoon remains available for optional networking, bilateral meetings, research collaboration, and professional follow-up.

Participate in EECCTM 2027

Non-presenting delegates may register directly. Researchers and clinicians wishing to present should submit an abstract for scientific review before completing presenter registration.

Submit Abstract Register